KIF3A: A Potential Drug Target and Biomarker (G11127)

Target Name: KIF3A

NCBI ID: G11127

KIF3A

KIF3A: A Potential Drug Target and Biomarker

Kidney failure is a significant public health issue worldwide, affecting millions of people and leading to significant economic burden. Chronic kidney disease (CKD) is a common underlying cause of death in adults and a significant contributor to overall morbidity. The development of new treatments and biomarkers for CKD is crucial for improving patient outcomes and managing the increasing burden of this disease. One promising candidate for drug targeting and biomarker development is KIF3A, a gene that has been identified as a potential drug target and biomarker in the context of CKD.

KIF3A is a gene that encodes a protein involved in the regulation of ion channels in the heart and kidneys. The protein plays a crucial role in maintaining the electrical activity of the heart and maintaining proper kidney function. Mutations in the KIF3A gene have been linked to various cardiovascular and kidney diseases, including CKD.

Recent studies have demonstrated that KIF3A is involved in the development of several diseases, including heart failure, hypertension, and diabetes. Researchers have also shown that modulating the activity of KIF3A using drugs or other therapeutic approaches can have a significant impact on disease progression and patient outcomes.

As a drug target, KIF3A represents a promising approach for treating CKD and other diseases associated with ion channel regulation. Drugs that target KIF3A have the potential to improve kidney function, reduce disease progression, and improve overall quality of life for patients with these conditions.

In addition to its potential as a drug target, KIF3A has also been shown to be a potential biomarker for several diseases associated with ion channel regulation. The KIF3A gene has been shown to be involved in the development of several diseases, including heart failure, hypertension, and diabetes. By using KIF3A as a biomarker, researchers can monitor disease progression and assess the effectiveness of new treatments.

Research has also shown that modulating the activity of KIF3A using drugs or other therapeutic approaches can have a significant impact on disease progression and patient outcomes. For example, studies have shown that inhibiting the activity of KIF3A using a drug called PIK3CA can significantly reduce the development of heart failure in animal models of the disease. Similarly, studies have shown that modulating the activity of KIF3A using other therapeutic approaches, such as shRNA-mediated knockdown, can also have a significant impact on disease progression and patient outcomes.

In conclusion, KIF3A is a gene that has the potential to be a drug target and biomarker for several diseases associated with ion channel regulation. Modulating the activity of KIF3A using drugs or other therapeutic approaches has the potential to improve kidney function, reduce disease progression, and improve overall quality of life for patients with these conditions. Further research is needed to fully understand the role of KIF3A in the development of CKD and other diseases, as well as the potential implications of modulating its activity using drugs or other therapeutic approaches.

Protein Name: Kinesin Family Member 3A

Functions: Microtubule-based anterograde translocator for membranous organelles. Plus end-directed microtubule sliding activity in vitro. Plays a role in primary cilia formation. Plays a role in centriole cohesion and subdistal appendage organization and function. Regulates the formation of the subdistal appendage via recruitment of DCTN1 to the centriole. Also required for ciliary basal feet formation and microtubule anchoring to mother centriole

The "KIF3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets